Inhibitors of quinolinic acid synthesis: New weapons in the study of neuroinflammatory diseases

Future Medicinal Chemistry

Volumn 6, Issue 8, 2014, Pages 841-843

  Costantino, Gabriele ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

inhibitors; kynurenine pathway; neuroinflammation; neuroprotection; quinolinic acid

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 3 HYDROXYKYNURENINE; AMINO ACID; CINNABARINIC ACID; EXCITOTOXIN; HYDROLASE; KYNURENIC ACID; KYNURENINASE; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; KYNURENINE 3 MONOOXYGENASE INHIBITOR; NEUROTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINIC ACID; OXYGENASE INHIBITOR; QUINOLINIC ACID; QUINOLONIC ACID PHOSPHORIBOSYLTRANSFERASE; TRYPTOPHAN; UNCLASSIFIED DRUG; 3 HYDROXYANTHRANILATE 3,4 DIOXYGENASE; ENZYME INHIBITOR; NICOTINIC RECEPTOR;

AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; CATABOLISM; CELL VIABILITY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMORADIOTHERAPY; CONVULSION; ENZYME INHIBITION; GLIOMA; HUMAN; HUNTINGTON CHOREA; IMMUNE RESPONSE; MEDICINAL CHEMISTRY; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CENTRAL NERVOUS SYSTEM DISEASES; CHEMISTRY; METABOLISM; PATHOLOGY; SYNTHESIS;

3-HYDROXYANTHRANILATE 3,4-DIOXYGENASE; CENTRAL NERVOUS SYSTEM DISEASES; ENZYME INHIBITORS; HUMANS; KYNURENIC ACID; QUINOLINIC ACID; RECEPTORS, NICOTINIC;

EID: 84903273505     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.35     Document Type: Review

References (15)

1. Stone TW, Stoy N, Darlington LG. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol. Sci. 34(2), 136-143 (2013).
2. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 13(7), 465-477 (2012).
3. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J. 279(8), 1356-1365 (2012).
4. Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 72, 411-412 (1981) (Pubitemid 11081065)
5. Schwarcz R, Köhler C. Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci. Lett. 38, 85-90 (1983).
6. Whetsell WO Jr, Schwarcz R. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system. Neurosci. Lett. 97, 271-275 (1989). (Pubitemid 19047470)
7. Beal M, Kowall N, Ellison D et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168-171 (1986). (Pubitemid 16022019)
8. Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ. Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease. Prog. Neurobiol. 90(2), 230-245 (2010).
9. Amori L, Guidetti P, Pellicciari R, Kajii Y, Schwarcz R. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J. Neurochem. 109(2), 316-325 (2009).
10. Pellicciari R, Natalini B, Costantino G et al.Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase. J. Med. Chem. 37(5), 647-655 (1994). (Pubitemid 24102185)
11. Röver S, Cesura AM, Huguenin P, Kettler R, Szente A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J. Med. Chem. 40(26), 4378-4385 (1997). (Pubitemid 28042317)
12. Lee WS, Lee SM, Kim MK et al. The tryptophan metabolite 3-hydroxyanthranilic acid suppresses T cell responses by inhibiting dendritic cell activation. Int. Immunopharmacol. 17(3), 721-726 (2013).
13. Fazio F, Lionetto L, Molinaro G et al. Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. Mol. Pharmacol. 81(5), 643-656 (2012).
14. Sahm F, Oezen I, Opitz CA et al. The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. Cancer Res. 73(11), 3225-3234 (2013).
15. Vallerini GP, Amori L, Beato C et al. 2-aminonicotinic acid 1-oxides are chemically stable inhibitors of quinolinic acid synthesis in the mammalian brain: a step toward new antiexcitotoxic agents. J. Med. Chem. 56(23), 9482-9495 (2013).